DTIL — Precision Biosciences Share Price
0.000.00%
Last trade - 00:00- $60.66m
- -$3.33m
- $68.70m
- 31
- 69
- 24
- 36
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.08 | ||
| Price to Tang. Book | 1.09 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.88 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -21.55% | ||
| Return on Equity | 19.05% | ||
| Operating Margin | -38.08% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 24.29 | 115.53 | 25.1 | 48.73 | 68.7 | 21.97 | 28.6 | 25.3% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Precision BioSciences, Inc. is a clinical-stage gene editing company dedicated to improving life (DTIL) with its proprietary ARCUS genome editing platform. Using ARCUS, the Company’s pipeline is comprised of in vivo gene editing candidates designed to deliver cures for a range of genetic and infectious diseases. The ARCUS platform is used to develop in vivo gene editing therapies for gene edits, including gene insertion, elimination, and excision. The Company's in vivo gene editing pipeline programs include PBGENE-HBV, PBGENE-3243, PBGENE-DMD, PBGENE-LIVER, PBGENE-CNS, PBGENE-NVS and iECURE-OTC. PBGENE-HBV is its lead in vivo gene editing program designed to eliminate cccDNA, the key source of replicating hepatitis B virus (HBV) and inactivating integrated HBV DNA in hepatocytes. Its PBGENE-3243 program is a first of its kind potential treatment for m.3243 associated mitochondrial disease. The Company's iECURE-OTC program is developed in partnership with iECURE, Inc.
Directors
- Kevin Buehler NEC (63)
- Michael Amoroso PRE (43)
- Alex Kelly CFO (54)
- Fayaz Khazi CEX (48)
- Derek Jantz CSO (45)
- Dario Scimeca GCN (46)
- Christopher Heery OTH
- Alan List OTH
- Shari Pire DRC
- Samuel Wadsworth DRC (69)
- Stanley Frankel IND (62)
- Geno Germano IND (60)
- Raymond Schinazi IND (71)
- Shalini Sharp IND (46)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- January 26th, 2006
- Public Since
- March 28th, 2019
- No. of Shareholders
- 29
- No. of Employees
- 108
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 10,550,053
- Address
- 302 E Pettigrew St Ste A100, DURHAM, 27701-2393
- Web
- https://precisionbiosciences.com/
- Phone
- +1 9193145512
- Auditors
- Deloitte & Touche LLP
Upcoming Events for DTIL
Precision BioSciences Inc Annual Shareholders Meeting
Precision BioSciences Inc Annual Shareholders Meeting
Q2 2025 Precision BioSciences Inc Earnings Release
Q3 2025 Precision BioSciences Inc Earnings Release
Similar to DTIL
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
What is the Precision Biosciences share price?
As of Today at 22:44 UTC, shares in Precision Biosciences are trading at $5.75. This share price information is delayed by 15 minutes.
How has the Precision Biosciences share price performed this year?
Shares in Precision Biosciences last closed at $5.75 and the price had moved by -46.96% over the past 365 days. In terms of relative price strength the Precision Biosciences share price has underperformed the S&P500 Index by -52.17% over the past year.
What are the analyst and broker recommendations for Precision Biosciences?
The overall consensus recommendation for Precision Biosciences is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Precision Biosciences dividend yield?
Precision Biosciences does not currently pay a dividend.
Does Precision Biosciences pay a dividend?
Precision Biosciences does not currently pay a dividend.
When does Precision Biosciences next pay dividends?
Precision Biosciences does not currently pay a dividend.
How do I buy Precision Biosciences shares?
To buy shares in Precision Biosciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Precision Biosciences?
As of the previous close price of $5.75, shares in Precision Biosciences had a market capitalisation of $60.66m.
Where are Precision Biosciences shares listed?
Here are the trading details for Precision Biosciences:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: DTIL
What kind of share is Precision Biosciences?
Based on an overall assessment of its quality, value and momentum Precision Biosciences is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Precision Biosciences share price forecast for 2025?
The analyst consensus target price for shares in Precision Biosciences is $21.50. That is 273.91% above the last closing price of $5.75.
Analysts covering Precision Biosciences currently have a consensus Earnings Per Share (EPS) forecast of -$6.38 for the next financial year.
Find out moreWhat is the trend in the Precision Biosciences share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Precision Biosciences. Over the past six months, its share price has underperformed the S&P500 Index by -35.96%.
As of the last closing price of $5.75, shares in Precision Biosciences were trading -17.7% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Precision Biosciences PE Ratio?
The Precision Biosciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $5.75.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Precision Biosciences?
Precision Biosciences' management team is headed by:
- Kevin Buehler - NEC
- Michael Amoroso - PRE
- Alex Kelly - CFO
- Fayaz Khazi - CEX
- Derek Jantz - CSO
- Dario Scimeca - GCN
- Christopher Heery - OTH
- Alan List - OTH
- Shari Pire - DRC
- Samuel Wadsworth - DRC
- Stanley Frankel - IND
- Geno Germano - IND
- Raymond Schinazi - IND
- Shalini Sharp - IND